Kim JT, Park MS, Choi KH, et al. - In 4,461 individuals, aged 69 ± 13 years, with acute, nonminor, and noncardioembolic stroke, researchers compared the efficacy of dual antiplatelet therapy with clopidogrel plus aspirin with that of aspirin monotherapy (AM). Acute (within 24 hours of onset), nonminor (baseline National Institutes of Health Stroke Scale score, 4–15), and noncardioembolic stroke patients were identified using a prospective, nationwide, multicenter stroke registry database. It was noted that 52.5% (n = 2,340) received AM, and 47.5% (n = 2,121) received DAPT among the patients meeting the eligibility criteria. Compared with AM, clopidogrel plus aspirin during the first 3 months after a nonminor, noncardioembolic, ischemic stroke did not lessen the risk of the primary outcome event.